Prolight Diagnostics receives positive feedback at ADLM Congress
Prolight Diagnostics recently participated at the ADLM congress in Chicago, where the company had the opportunity to present its point-of-care system Psyros to potential customers and partners.
– We are very encouraged by the congress as we noticed even greater interest from the large diagnostic companies than in previous years and consistently received very positive feedback from potential customers and partners, said CEO Ulf Bladin.
The ADLM (Association for Diagnostics & Laboratory Medicine) Congress is the leading international diagnostics congress, bringing together more than 20,000 decision makers, clinicians, laboratory specialists and key opinion leaders from around the world. The congress has been held for over 50 years, and this year it was held in Chicago from July 28 to August 1.
Swedish company Prolight Diagnostics exhibited at the congress, showcasing its digital point-of-care (POC) system Psyros, which can rapidly detect biomarkers in whole blood using Prolight’s proprietary single molecule counting technology. The launch product will be a high-sensitivity troponin I test, for the rule-in or rule-out of myocardial infarction.
Prolight Diagnostics’ POC system Psyros
According to the company, the Psyros system enables point-of-care testing in a range of clinical areas, including tests that can only be performed in central laboratories at this point in time. With Psyros, the analysis is carried out close to the patient, providing quick and reliable test results during the initial examination. Psyros can test a range of biomarkers with high sensitivity and accuracy, and the system is also multiplex capable, allowing the simultaneous measurement of biomarker panels.
– This could lead to a paradigm shift in point-of-care testing, which could ultimately lead to major health economic benefits, said CEO Ulf Bladin.
Extended network and follow-up meetings
According to Ulf Bladin, the ADLM congress was a huge success for the company. In addition to Ulf, the team in Chicago consisted of CTO Steve Ross and COO Karl Bullen.
– We consistently received very positive feedback from potential customers and partners, confirming that Prolight offers a new and innovative POC technology that could be of great benefit to healthcare and patients, said Ulf Bladin.
During the congress, the company had the opportunity to have face-to-face meetings with a range of existing contacts. Additionally, there was much interest at the booth, with visitors from across the globe, and the chance to explore new opportunities with potential partners.
– The majority of visitors immediately recognised the unique benefits of being able to carry out single molecule counting in such a simple cost-effective format. Additionally, our rapid rate of progress was commented on by both our existing contacts and new visitors to the booth, said CTO Steve Ross
During the congress, Prolight also had a number of face-to-face meetings with representatives from the major global diagnostics companies.
– This year we noticed even greater interest from the large diagnostic companies than in previous years, which we attribute to our rapid progress over the last 12 months. Relationships with global partners do take time, but our list of potential partners is continuing to expand. We expect interest to further increase towards the end of this year as we enter verification and validation activities and start to generate initial clinical data from our upcoming study at St Thomas’ Hospital in London, said CEO Ulf Bladin.
Details on the feedback and next development steps
During the ADLM congress, Prolight showcased the Psyros prototype instrument and final cartridge design at their booth. In addition, the system was also on display at the booths of two of the company’s key partners, G&H | ITL and Flex Medical. G&H | ITL is the partner for the design and manufacture of the instrument and Flex Medical is the contract manufacturer for the disposable cartridge.
– There was great interest at both booths, which enhanced Prolight’s overall presence at the congress. Visitors to the Flex booth were impressed with the simplicity of the cartridge design and its suitability for large scale automated production, with one visitor describing it as “lateral flow level COGS but for IVD”. The low cost Psyros cartridge drew significant interest from distribution organisations who recognised the commercial opportunity that exists for a high sensitivity POC system with such a low cost cartridge, said COO Karl Bullen.
– Very positive feedback was also received regarding the compact instrument design and user interface. The next step in the instrument development program will be the delivery of fully functioning beta prototypes that will undergo testing, evaluation and verification in the third and fourth quarters of 2024, followed by transfer to the instrument manufacturing line by the end of the year. 2025 will see the start of the multicenter clinical performance study that will form the basis for regulatory submission, paving the way for commercial launch in 2026, said CTO Steve Ross.
Innehållet i BioStocks nyheter och analyser är oberoende men BioStocks verksamhet är i viss mån finansierad av bolag i branschen. Detta inlägg avser ett bolag som BioStock erhållit finansiering från.
